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Parkinson’s disease (PD) is a progressive neurodegenerative disorder, which is
characterized by neuroinflammation, dopaminergic neuronal cell death and motor
dysfunction, and for which there are no proven effective treatments. The negative
correlation between tobacco consumption and PD suggests that tobacco-derived
compounds can be beneficial against PD. Nicotine, the more studied alkaloid derived from
tobacco, is considered to be responsible for the beneficial behavioral and neurological
effects of tobacco use in PD. However, several metabolites of nicotine, such as cotinine,
also increase in the brain after nicotine administration. The effect of nicotine and some
of its derivatives on dopaminergic neurons viability, neuroinflammation, and motor and
memory functions, have been investigated using cellular and rodent models of PD. Current
evidence shows that nicotine, and some of its derivatives diminish oxidative stress and
neuroinflammation in the brain and improve synaptic plasticity and neuronal survival of
dopaminergic neurons. In vivo these effects resulted in improvements in mood, motor
skills and memory in subjects suffering from PD pathology. In this review, we discuss the
potential benefits of nicotine and its derivatives for treating PD.
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INTRODUCTION
Parkinson’s disease (PD) is the second most common neurode-
generative illness after Alzheimer’s disease (AD), and reaches
a prevalence of 3% after 65 years of age (Jellinger, 2003).
Parkinson’s disease is predominantly sporadic, and rarely familial.
The familial form of the disease can develop due to single genetic
mutations (Dexter and Jenner, 2013). Parkinson’s disease is char-
acterized by the presence of Lewy bodies, mainly composed of
alpha-synuclein fibrils, a depletion of dopamine (DA)-generating
neurons in substantia nigra pars compacta (SNc) and ventral
tegmental area (VTA) regions of the brain (Wirths and Bayer,
2003; Dexter and Jenner, 2013), that results in a decrease of DA
levels in the striatum and frontal cortex regions of the brain
Abbreviations: Aβ, beta-amyloid; AChE, acetylcholinesterase; AD,
Alzheimer’s disease; Akt (PKB), protein kinase B; DA, Dopamine; DMXBA,
3-(2,4-dimethoxy) benzylidene-anabaseine dihydrochloride; FPD, familial
PD; GSK3β, glycogen synthase kinase 3β; FS, forced swim; iNOS, the
inducible nitric oxide synthase; MAOIs, monoamine oxidase inhibitors; MT,
metallothionein; NFκB, neurothrophic factor kappa B; nAChRs, nicotinic
acetylcholine receptors; NMDA, N-methyl-D-aspartate; PAM, positive
allosteric modulator; PD, Parkinson’s disease; PI3K, phosphatidylinositol
3-kinase; PIB, Pittsburgh compound B; PSD95, postsynaptic density protein
95; SNc, substancia nigra pars compacta; TNF, tumor necrosis factor; VTA,
ventral tegmental area.
(Thompson et al., 2005). Parkinson’s disease affects cognitive and
motor abilities (Riedel et al., 2014), and progressively impairs
sleep (Dos Santos et al., 2014), attention, and short-term memory,
as well as visuospatial and executive functions (Liu et al., 2012;
Conte et al., 2013; Rottschy et al., 2013; Zokaei et al., 2014). The
dopaminergic deficit observed in PD patients seems to underlie
the motor impairment symptoms such as hypokinesia, tremor
and rigidity (Murer and Moratalla, 2011).
The cause of death of dopaminergic neurons is still a mystery;
however, actual evidence is consistent with the idea that oxida-
tive stress, mitochondrial dysfunction and neuroinflammation
are the main factors involved in the etiology of PD (Büeler,
2010; Zuo and Motherwell, 2013; Camilleri and Vassallo, 2014;
Celardo et al., 2014). It has been proposed that various genetic
and environmental factors causing mitochondrial dysfunction
result in abnormal accumulation of miscoded proteins and the
generation of oxidative stress in the brain of subjects with PD
(Bové and Perier, 2012; Cabezas et al., 2012, 2014; Perier and Vila,
2012; Dexter and Jenner, 2013; Trinh and Farrer, 2013; Zuo and
Motherwell, 2013; Figure 1).
Mild cognitive impairment later progressing to dementia is
commonly found in patients with PD (Aarsland et al., 2010; Hu
et al., 2014). Dementia develops in approximately 80% of PD
patients after 20 years with the condition (Cummings, 1988a,b;
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FIGURE 1 | Potential etiological factors of Parkinson’s disease.
Current evidence suggests that environmental factors and genetic risk
factors provoking oxidative stress, excitotoxicity and mitochondrial
dysfunction in the brain can lead to the degeneration of the midbrain
dopaminergic system, resulting in PD. In PD, the generation of protein
aggregates may disrupt the mitochondrial membrane potential and
induce abnormal Ca2+ influx, impaired respiratory enzyme activities,
reduced ATP generation and increased levels of reactive oxygen
species. Also, abnormal release of cytochrome C from damaged
mitochondria can trigger the activation of the apoptotic signaling
cascades and the release of caspases, resulting in neuronal cell death.
The generation of free radicals may then result in further damage to
cellular macromolecules and organelles through nitrosylation, oxidation,
and peroxidation, directly contributing to neuronal injury.
Hughes et al., 2000). New evidence also suggests that the level
of alpha-synuclein in the cerebral spine fluid can predict the
progression of cognitive decline but not of motor dysfunction
in PD (Stewart et al., 2014). Dementia in PD is also associated
with the accumulation in the central nervous system of pro-
tein aggregates such as β-amyloid peptide (Aβ) also present in
other neurological conditions such as AD (Mandal et al., 2006;
Kalaitzakis et al., 2008). The analysis of 30 PD cases from the
United kingdom PD’s society showed that Aβ deposition in the
striatum strongly correlated with dementia in humans suggesting
that this accumulation is a contributing factor for the devel-
opment of cognitive impairment and neurodegeneration in this
condition (Mandal et al., 2006; Kalaitzakis et al., 2008). Subjects
with PD and dementia show degeneration of several subcortical
nuclei, including the cholinergic nucleus basalis of Meynert, the
medial SN, and the noradrenergic locus coeruleus (LC; Shin et al.,
2012). It has been postulated that the presence of secondary
neuropathologies may further increase oxidative stress, decrease
brain energy and enhance the degenerative process in the brain
of subjects with PD (Sasaki et al., 1992; Kurosinski et al., 2002;
Slawek et al., 2008).
OXIDATIVE STRESS, NEUROINFLAMMATION, PROTEIN
AGGREGATION AND BRAIN ENERGY DEFICITS IN
PARKINSON’S DISEASE
Oxidative stress plays a key role, inducing damage to neuronal
proteins, lipid and organelles in the SN of subjects with PD
(Cabezas et al., 2012). Also as mentioned above abnormal aggre-
gation and/or mutation of proteins such as beta amyloid, DJ-
1, PTEN-induced putative kinase 1, parkin, leucine-rich repeat
kinase 2 and α-synuclein have been observed in PD (el-Agnaf
and Irvine, 2002; Nunomura et al., 2007; Alcalay et al., 2009).
Families with autosomal dominant early-onset of familial PD
(FPD) commonly present mutations in the α-synuclein gene
A53T, A30P and E46K that accelerate α-synuclein aggregation
(Corti et al., 2011; Roth, 2014). In addition to protein mutations,
environmental factors such as pesticides, ethanol consumption,
metals and the accumulation of somatic mitochondrial DNA
mutations have been observed in the SNc during aging and PD
(Zuo and Motherwell, 2013) that may negatively affect brain
homeostasis leading to neurodegeneration (Perez et al., 2010;
Perfeito et al., 2013; Roth, 2014). Protein aggregation may dis-
rupt the mitochondrial membrane potential, impair respiratory
enzyme activities and result in reduced ATP generation, energy
deficits and increased levels of reactive oxygen species (O2−
and H2O2). In fact, energetic and antioxidant compounds are
considered to have beneficial effects against PD (Klein and Fer-
rante, 2007; Sutachan et al., 2012). In turn, oxidative stress can
also affect protein degradation by deteriorating the ubiquitin-
proteasome system (Díaz et al., 2010; Perfeito et al., 2013).
Furthermore, the release of cytochrome C from damaged mito-
chondria can trigger the activation of apoptotic cascades and
neuronal cell death (Tatton et al., 2003). Also, free radical gen-
eration can promote nitrosylation, oxidation, and peroxidation
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of neuronal proteins, making the surviving neurons increas-
ingly susceptible to further toxic insults (Barreto et al., 2011,
2014a).
Neuroinflammation and microglia activation seem to play
an important role in PD pathogenesis (Tansey and Goldberg,
2010). Microglia represents about 10–15% of glial cells in the
brain, and changes in the brain homeostasis induced by abnormal
proteins aggregation, brain injury, and hypoxia, stimulate the
release of reactive oxygen and nitrogen species, cytokines, and
chemokines from these immune cells (Wyss-Coray and Mucke,
2002; McGeer and McGeer, 2004; Barreto et al., 2007, 2009,
2014b; Albarracin et al., 2012; Sutachan et al., 2012; Torrente
et al., 2014). Microglia activation may have some beneficial effects
helping with the clearance of aggregated proteins and cell debris.
However, it is considered that persistent microglia activation
further damages the brain and exacerbates the neurodegenerative
process in PD.
A recent clinical study investigated the relationship between
microglial activation, amyloid deposition, and glucose
metabolism in 19 PD patients with and without dementia
and 24 healthy controls subjects (Edison et al., 2013). Patients
were evaluated using T1 and T2 magnetic resonance imaging
(MRI) technology, and positron emission tomography (PET)
scans, for the in vivo visualization of microglia activation
glucose metabolism, and beta amyloid deposits by using the
radiotracer [11C](R)-PK11195, [18F] fluoro-deoxy-glucose, and
[11C]Pittsburgh compound B(PIB), respectively (Edison et al.,
2013). Parkinson’s disease patients with dementia showed higher
cortical microglia activation than healthy controls, a sign of
neuroinflammation. In addition, a modest but consistent increase
in Aβ deposition expressed as a slightly higher [11C] PIB uptake
was observed in the cortex of PD patients. Microglia activation
and energy deficits (glucose metabolism deficiency) are early
events during the development of PD. Furthermore, the reduction
in both glucose metabolism and microglia activation correlated
with a decrease in mini-mental state examination score, a broadly
used test of cognitive abilities. Altogether, this evidence suggests
that these factors are relevant to the development of cognitive
impairment and are good therapeutic targets for PD.
NICOTINE AND ITS DERIVATIVES AS THERAPEUTIC AGENTS
AGAINST PARKINSON’S DISEASE
In spite of over almost 200 years passed from its discov-
ery, there are no drugs available to slow down or stop
the progression of PD (Connolly and Lang, 2014). Motor
symptoms in PD can be improved by N-methyl-NMDA block-
ers as well as using dopaminergic and anticholinergic com-
pounds. However, the cognitive deficits are not substantially
improved by the current therapeutic interventions (Lorenz
et al., 2014). Furthermore, the most used anti-PD drug,
levodopa, produces severe toxic effects such as restlessness,
mental impairment, mood changes, and after prolonged use
(3–5 years), dyskinesia (Simuni and Sethi, 2008). For this rea-
son, the development of potential new therapeutic approaches is
imperative.
In the PD brains, one of the regions more affected by the
disease, the SNc, contains surviving neurons that may differ
FIGURE 2 | Illustrative view of the potential mechanisms of action of
nicotinic analogs to prevent Parkinson’s disease.
from the healthy ones by presenting Lewy bodies, neurome-
lanin and/or showing negative immunoreactivity for tyrosine
hydroxylase (Faucheux et al., 2003; Hirsch et al., 2003a,b).
These neurons may be a good target for neuroprotective or
restorative therapeutic strategies, focused in decreasing oxidative
stress and neuroinflammation. Studies revealed that choliner-
gic and dopaminergic systems work together to fine tune the
striatum control of motor and cognitive functions. Then cholin-
ergic dysfunction also may contribute to the neurotransmit-
ter imbalance underlying PD (Zhou et al., 2003; Aosaki et al.,
2010).
The striatum receives abundant cholinergic innervations.
The neurons of the striatum express various types of mus-
carinic (mAChR) and nicotinic acetylcholine receptors (nAChRs),
as well as DA receptors (Zhou et al., 2003). The cholin-
ergic receptors modulate the dopaminergic system and are
involved in motor and cognitive functions. Different subtypes
of nAChRs are differentially expressed throughout the central
nervous system and show diverse subunit composition includ-
ing α3, α4, α5, α6 and α7, β2, α3 and β4 (Graham et al.,
2002). In humans, the nicotinic receptors subtypes undergo
changes during aging (Nordberg, 1994). Significant losses of
nAChRs subunits α7 and α4 have been detected in the cortex
from PD patients (Whitehouse et al., 1988; Burghaus et al.,
2003).
Most immune cells such as B cells, monocytes and T cells
express all subtypes of mAChRs (M1-M5), and the α3, α5,
α7, α9, and α10 nAChR subunits and modulators of the
AChRs can influence immunological response and inflam-
mation (Gahring and Rogers, 2005; Carnevale et al., 2007).
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Nicotinic acetylcholine receptors regulate synaptic transmis-
sion and synaptic plasticity, in several regions of the brain
including the midbrain DA centers. These receptors are ligand-
gated Ca2+, Na+ and K+ channels, whose activation causes
membrane depolarization and the increase of both intraneu-
ronal calcium levels and neurotransmitter release probability.
At the postsynaptic sites the activation of the nAChRs also
stimulates cell signaling pathways promoting the expression of
synaptic proteins mediating, at cellular level, higher cognitive
functions such as attention, learning and memory and other
cognitive functions (McKay et al., 2007). Furthermore, it has
been shown that nAChRs activation prevents neurodegenera-
tion by mechanisms involving the activation of pro-survival
signaling factors such as phosphatidylinositol 3-kinase (PI3K),
Akt and Bcl proteins in the brain (Kawamata and Shimohama,
2011).
In addition, modulators of the nAChRs such as nicotine,
can have beneficial effects by stimulating cholinergic anti-
inflammatory pathways (Gahring and Rogers, 2005). One of
these pathways, involves the control of the immune response
by the efferent vagus nerve, via the peripheral release of ACh
that in turn activates the cholinergic receptors in the brain.
Acetylcholine by stimulating the α7nAChR inhibits the activity
of the pro-inflammatory neurothrophic factor kappa B (NFκB)
in human macrophages and consequently the expression and
release of cytokines such as the tumor necrosis factor (TNF)
by these immune cells (Balakumar and Kaur, 2009). In fact, a
knockout mouse showing a genetic deletion of the α7nAChR
presented a significant increase in pro-inflammatory cytokines
such as TNF-α, interferon-γ and IL-6 in spleen cells. This evidence
showed that α7nAChRs are involved in the regulation of cytokine
production (Fujii et al., 2007).
In rats, all dopaminergic neurons in the SNc express the
α7nAChR (Yanagida et al., 2008). Since the α7nAChR activation
stimulates signaling pathways that are anti-inflammatory and
promote neuronal survival, the positive modulation of these
receptors can be relevant for preventing neuroinflammation and
promoting neuronal survival in the brain regions affected by PD.
In this respect, several nicotinic receptors subunits such as the α7,
α6β2 and α4β2 have been proposed as targets against PD (Quik
and Wonnacott, 2011c).
Several epidemiological studies have shown that tobacco users
have a lower incidence or severity of PD (Baron, 1996). A meta-
analysis of four cohorts and 44 single-subject studies, showed a
40% decrease of risk of developing PD for smokers when com-
pared to never smokers (Hernán et al., 2002). In addition, another
study reported evidence suggesting that smoking prevented motor
complications in a group of PD patients (De Reuck et al., 2005).
Together with smoking, other natural products such as caffeine
have shown to be preventative against PD. In one of these stud-
ies (Hernán et al., 2002), the epidemiological evidence on the
association between cigarette smoking, coffee drinking, and the
odds of developing PD was reviewed. Results for smoking were
calculated based on 44 case-control and four cohort studies, and
for coffee on eight case-control and five cohort studies. Compared
with never smokers, the relative risk of PD was 0.59 for ever
smokers, 0.80 for past smokers, and 0.39 for current smokers.
Compared with non-exposed to caffeine controls, relative risk
of PD was 0.69 for coffee drinkers. The relative risk per three
additional cups of coffee per day was 0.75 in case-control studies
and 0.68 in cohort studies. This meta-analysis showed strong
epidemiological evidence supporting that in addition to nicotine
also caffeine decreased the risk of PD (Chen et al., 2010).These
findings have been confirmed by several large prospective studies
for either coffee or cigarette consumption. Interestingly, other
caffeine-containing beverages, such as black tea and Japanese and
Chinese teas also reduced PD risk. Because numerous studies
reported had lower sample size or limited longitudinal data, the
relationship between tobacco consumption and lower risk to
develop PD has been interpreted differently. For example, based in
small case studies, some authors have suggested that PD patients
display specific personality traits, such as lack of novelty seeking,
that make them less prone to consume stimulants such as tobacco
and coffee. A case-control study assessed the relationship between
the ability to quit smoking and nicotine substitute use, in 1808
patients with PD and 1876 sex and age matched controls (Ritz
et al., 2014). Data from this study revealed that PD patients quit
smoking more easily than controls. The authors suggested that
this finding was the result of a decreased sensitivity to nicotine
in PD patients. Furthermore, they proposed that superior ability
to quit smoking is an early sign of PD, similar to constipation,
olfactory dysfunction, and sleep disorders. They also suggested
that the positive effect of smoking revealed by epidemiologic
studies was the result of reverse causation and not a protective
effect of nicotine per se.
Albeit an interesting observation, newly published evidence,
in agreement with previous studies, strongly supports the view
that smoking was neuroprotective against PD. The analysis of
longitudinal data from 305,468 participants of the NIH-AARP
Diet and Health cohort, of whom 1662 had a PD diagno-
sis, clearly showed that the number of cigarettes and years
of smoking inversely and significantly correlated with dimin-
ished odds of developing PD. Compared with non-smokers,
the odds ratios were 0.78 for past smokers and 0.56 for cur-
rent smokers. Furthermore, the time of smoking was linked
to a lower risk of developing PD. When compared with non-
smokers, the odds ratio among past smokers decreased with
the smoking duration. Thus, the odds ratio for those who
smoked more than 20 cigarettes per day per 1–9, 10–19,
20–29 and 30 years were 0.96, 0.78, 0.64 and 0.59, respectively.
These studies strongly suggest that caffeine and nicotine are
neuroprotective.
About the mechanism of neuroprotection, in addition to the
mechanisms discussed, a new hypothesis proposes that both
cigarette and coffee exert their effects by a completely different
mechanism. The hypothesis states that tobacco and caffeine both
exert their effects by changing the composition of the micro-
biota in the gut and consequently reducing intestinal inflam-
mation since pro-inflammatory cytokines are also produced by
enteric glial cells (EGC) in the gut (Derkinderen et al., 2014).
According to this hypothesis, inflammation would promote α-
synuclein aggregation within enteric neurons (EN). The aggre-
gated protein thus may spread to the central nervous system via
the vagal preganglionic innervation of the gut and the dorsal
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motor nucleus of the vagus (DMNV). After several years, the
LC and the SN will become affected. Thus, the decrease of
inflammation induced by nicotine and caffeine will decrease α-
synuclein aggregation in enteric nerves, and its propagation to the
brain. This effect will reduce neurodegeneration and reduce the
risk of PD.
The neuroprotective effect derived from a general reduction
of systemic inflammation is an interesting idea that merit further
investigation. Certainly, we consider reasonable to propose that
the anti-inflammatory effects of nicotine and nicotine-derived
compounds is a key contributor to their neuroprotective effects
in the brain.
The neuroprotective effect of tobacco has been mainly
attributed to nicotine, a naturally occurring alkaloid from tobacco
that consistently showed beneficial pro-cognitive effects in cel-
lular and animal models of PD (Parain et al., 2003). The
positive effect of nicotine on motor coordination and behav-
ior has been attributed to its ability to increase DA avail-
ability and reduce the production of reactive oxygen species.
Although, the detailed mechanism of neuroprotection is not well
understood, the activation of nAChRs is considered the main
mechanism of action of nicotine against PD (Budzianowski,
2013).
The derivative of synthetic heroin, 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP), elicits PD-like symptoms in exper-
imental primates and rodents and drug addicts, giving a clear
clue that environmental factors may be involved in the devel-
opment of this disease (Quik et al., 2006a,b). In fact, acute
exposure to MPTP induces striatal neurodegeneration in the
brain of primates, mimics many of the characteristics of PD
pathology. Chronic nicotine treatment protected against MPTP-
induced synaptic plasticity and dopaminergic dysfunction, as well
as prevented striatal neurodegeneration in non-human primates
(Quik et al., 2006a,b). This beneficial effect of nicotine was
also observed in another model of PD, the methamphetamine-
induced neurotoxicity in rodents (Maggio et al., 1997). Inter-
estingly, they found that (-)-nicotine’s actions correlated with
an increase in the expression of the neurotrophic factors, the
basic fibroblast growth factor-2 and the brain-derived neu-
rotrophic factor in the rat striatum. The effect of (-)-nicotine
on the induction of fibroblast growth factor 2 was pre-
vented by the nAChR antagonist mecamylamine (Maggio et al.,
1997).
This evidence further supported the view that the neuropro-
tective effects of nicotine were the result of nAChRs stimula-
tion, which promotes DA release and increases the survival of
dopaminergic neurons by activating anti-apoptotic factors. These
results are coherent with the idea that nicotine may prevent PD by
stimulating the expression of neuroprotective signaling factors in
the brain.
Also, the effects of nicotine and cotinine on L-DOPA-induced
dyskinesias have been investigated in L-DOPA-treated unilateral
6-hydroxydopamine-lesioned rats, a well-established model of
dyskinesia. By using this model, it was found that daily treatment
with nicotine (0.1–0.2 mg/kg, for 4 or 10 days) but no coti-
nine, reduced the abnormal involuntary movements. The effect
was not observed after acute nicotine administration. Several
days of mecamylamine (1.0 mg/kg) injection also ameliorated
dyskinesias to a comparable extent to nicotine, suggesting that
the latter may have exerted its effects by desensitizing nAChRs.
Another study tested the protective potential of ABT-107, a
highly selective agonist of the α7 nAChRs in rats lesioned by
infusion of 6-hydroxydopamine (6-OHDA) into the medial fore-
brain (Bordia et al., 2014) were implanted with mini pumps
containing ABT-107 or nicotine. They found that 2-week treat-
ment with ABT-107 or nicotine in rats, improved two measures
of Parkinsonism, the contralateral forelimb use and adjusted
stepping. These treatments also significantly improved stria-
tum integrity and basal DA release from lesioned striatum, as
well as nicotine-stimulated DA release mediated via α4β2 and
α6β2 nAChRs. In summary, epidemiological studies consistently
have shown a lower risk of PD among smokers suggesting that
this association is causal (Mellick et al., 2006; O’Reilly et al.,
2009).
One latest study investigated the effect of two β2 nAChR
agonists, ABT-089 and ABT-894, on levodopa-induced dyskine-
sias (LIDs) in 1-MPTP-lesioned monkeys. Monkeys were admin-
istered levodopa/carbidopa until they were stably dyskinetic.
Each set had a vehicle-treated group, a nAChR agonist-treated
group, and a nicotine-treated group as a positive control. For
the experiments with nAChR agonist, two groups of monkeys
were used, one group has been previously treated with nAChR
drugs (nAChR drug-primed), and a second group was nAChR
drug-naive. Both groups were treated with the partial agonist
ABT-089 orally for 5 days a week 30 min before levodopa, with
each dose given for 1–5 weeks. ABT-089 decreased LIDs by
30% to 50% compared with vehicle-treated monkeys. Nicotine
reduced LIDs by 70% in a parallel group. After 4 weeks of
washout, the effect of the full agonist ABT-894, was assessed
on LIDs in both groups. ABT-894 reduced LIDs by 70%, sim-
ilar to nicotine. Both drugs acted equally well at α4β2 and
α6β2 nAChRs. Tolerance did not develop for the time peri-
ods tested (range, 3–4 months). The nAChR drugs did not
induce significant side effects, and were effective to manage LIDs
in PD.
This evidence suggests that positive modulators of the
nAChRs, such as cotinine, can be excellent drugs to minimize LID
in PD (Zhang et al., 2014).
Together, this evidence supports the view that α7 nAChR
agonists may improve motor behaviors associated with PD by
enhancing striatal dopaminergic function.
On the other hand, evidence suggests that nicotine binds
and inhibits the fibrillation of both α-synuclein (Hong et al.,
2009) and Aβ (Zeng et al., 2001), thus preventing its toxic
effects. The presynaptic protein, α-synuclein is broadly expressed
in the brain and its aggregation is a pathological hallmark
of several neurodegenerative diseases, including PD (el-Agnaf
and Irvine, 2002; Schmid et al., 2013). The effects of sev-
eral tobacco compounds including anabaseine, cotinine, hydro-
quinone, nicotine and nornicotine on α-synuclein fibrillation
have been studied using atomic force microscopy, gel elec-
trophoresis, size exclusion chromatography–high performance
liquid chromatography and thioflavin assays. Using these tech-
niques, they discovered that nicotine and, at a lower extent,
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hydroquinone, inhibited α-synuclein fibrillation by stabilizing the
soluble oligomeric forms of the protein. These data indicated
that nicotine in addition to its cholinergic effects may prevent
the generation of toxic protein aggregates of α-synuclein in the
brain. Similar experiments showed an inhibition of Aβ peptide
aggregation by cotinine in vitro and in vivo (Echeverria et al.,
2011). On the other hand, research evidence from a separated
study, suggests that a decrease in protein misfolding induced
by these compounds can also be due to a reduction of pro-
tein aggregation by their direct binding to α-synuclein. This
study investigated the binding of caffeine, curcumin, and nico-
tine to α-synuclein by nano pore analysis. They found that these
compounds bind to α-synuclein causing large conformational
changes in it. This changes may affect the aggregation of this
protein resulting in another neuroprotective effect. Interestingly
caffeine and nicotine seems to bind to α-synuclein simultaneously
(Tavassoly et al., 2014).
NICOTINE METABOLITES
Nicotine is metabolized by the enzymes cytochrome P450 2A6
(CYP2A6), UDP-glucuronosyl transfease and flavin-containing
monooxygenase. The metabolism of nicotine is greatly affected
by genetic factors influencing CYP2A activity, diet components
such as grape fruit, age, sex, the use of estrogen, pregnancy
and kidney disease, and other medications. People treated with
nicotine have sustained brain levels of cotinine (Bergen and
Caporaso, 1999), thus cotinine may underlie at least in part the
beneficial effects of nicotine in PD. Nicotine is metabolized in the
liver to six primary metabolites, cotinine, nicotine N ′-oxide, nor-
nicotine, hydroxynicotine, anbaseine (Benowitz et al., 1994). In
addition, Nicotine 2′-hydroxylation produces 4-(methylamino)-
1-(3-pyridyl)-1-butanone with 2′-hydroxynicotine as an inter-
mediate. 2′-hydroxynicotine also yields nicotine-∆1′(2′)-iminium
ion. 4-(methylamino)-1-(3-pyridyl)-1-butanone that is further
metabolized to 4-oxo-4-(3-pyridyl) butanoic acid and 4-hydroxy-
4-(3-pyridyl) butanoic acid 9 (Hecht et al., 2000). Nicotine
N′-oxide, (4–7% of nicotine metabolism) is synthesized by
a flavin-containing monooxygenase 3 (Cashman et al., 1992;
Benowitz and Jacob, 1994). Following the systemic admin-
istration of nicotine, its metabolites cotinine, nornicotine,
and norcotinine can be found in the brain (Neurath, 1994).
Currently, the effect(s) of these metabolites and newly syn-
thetized derivatives against neurodegeneration is under intense
scrutiny.
COTININE
Cotinine is a component of the tobacco leaves and the main
metabolite of nicotine, with about 70–80% of nicotine being
converted to cotinine in a two-step process that is dependent
on the genetic background (Benowitz et al., 1996, 2011).
The first step, catalyzed by CYP2A6, involves the synthesis
of nicotine-∆1
′(5′)-iminium ion, which is in equilibrium
with 5′-hydroxynicotine. The second step, catalyzed by
an aldehyde oxidase, produces cotinine (Benowitz et al.,
2009). In addition, six main metabolites of cotinine have
been reported in humans: 3′-hydroxycotinine (McKennis
et al., 1963; Neurath, 1994), 5′-hydroxycotinine (also called
allohydroxycotinine) that exists in tautomeric equilibrium
with the open chain derivative 4-oxo-4-(3-pyridyl)-N-
methylbutanamide (Neurath, 1994), cotinine N-oxide, cotinine
methonium ion, cotinine glucuronide, and norcotinine (also
called dimethylcotinine) (Benowitz and Jacob, 1993, 1994,
1997).
The total clearance of nicotine averages about 1200 ml min−1.
Clearance of nicotine is decreased in the elders (age >65) com-
pared to adults (Molander et al., 2001). Neonates have dimin-
ished nicotine metabolism, and have a nicotine half-life three
to four times longer than in adults (Dempsey et al., 2000). The
metabolism of cotinine is much slower than that of nicotine.
Clearance of cotinine and (3′R, 5′S)-trans-3′-hydroxycotinine
is slow and averages about 45 ml min−1 and 82 ml min−1,
respectively. Distinctive from nicotine, cotinine does not have
addictive or major negative side effects in humans and its half-
life has shown to be similar in neonates, older children, and
adults (Dempsey et al., 2000, 2013). The clearance of nicotine is
more influenced by changes in hepatic blood flow than cotinine
whose clearance is more dependent on enzymatic metabolism.
Neonates have only slightly lower amounts of CYP2A6, CYP2D6,
and CYP2E1 protein in liver, whereas the CYP2B6 amount is
clearly lower in neonates than both adults and older children.
Several studies in animal models of the disease have shown that
cotinine is a memory enhancer that prevents cognitive impair-
ment induced by different neurological and mental conditions
including chronic psychological stress, antagonism of the NMDA
receptors, agonism of the DA receptors and the development
of AD-like pathology in rodents (Moran, 2012). Cotinine also
showed neuroprotective effects against Aβ toxicity in primary
neurons (Burgess et al., 2012) and glutamate in PC12 cells
(Buccafusco and Terry, 2003). More importantly, chronic treat-
ment of transgenic AD mice with cotinine, before full pathology
development, prevented memory loss and reduced plaque aggre-
gation in the brain of mice (Echeverria et al., 2011; Echeverria
and Zeitlin, 2012). Furthermore, twice the daily dose of cotinine
(5 mg/kg) administered after full development of the pathology
for a few months also improved working and reference memory,
reduced plaque pathology and increased the expression of the
postsynaptic density protein 95 (PSD95) in the hippocampus of
the AD mice (Grizzell et al., 2014). The positive effect of cotinine
on memory seems not to be restricted to rodents, as pro-cognitive
effects of cotinine have been also shown in monkey models
of schizophrenia and aging (Buccafusco and Terry, 2003, 2009;
Terry et al., 2012). New evidence showed that cotinine preserves
synaptic density by preventing synaptic loss induced by chronic
stress (Moran, 2012; Grizzell et al., 2014).
Since the cholinergic and dopaminergic systems influence each
other in the brain (Aosaki et al., 2010; Havekes et al., 2011), it
is expected that cholinergic agonist/modulators may affect the
dopaminergic system. An ideal treatment for PD should reduce
damage of dopaminergic neurons in midbrain; in this respect
interestingly, it has been shown that both nornicotine, and coti-
nine evoke DA release from striatal and cortical slices in rats,
respectively (Dwoskin et al., 1999). In vitro studies showed that
cotinine evoked (3H)DA- release at concentrations similar to the
ones estimated to be reached in the brain of smokers ( >1 µM,
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EC50 = 30 µM ). Cotinine was less potent than either nicotine or
nornicotine in inducing the release of DA (Dwoskin et al., 1999).
These effects were mediated by the nAChRs as were blocked by
their antagonists, mecamylamine and DHBE. On the other hand,
nornicotine, similarly to nicotine, activated the neural mechanism
responsible for behavioral sensitization. Since behavioral sensiti-
zation would be dependent on the activation of DA systems, and
nornicotine evokes DA release, these results suggest a significant
role for nornicotine in the behavioral sensitization produced by
nicotine.
Regarding potential therapeutic targets of nicotine-derived
compounds, the nAChRs subtypes, α6 β2 β3 and α6 α4 β2 β3,
play a key role in modulating dopaminergic function in the
mesolimbic and nigrostriatal dopaminergic pathways. Since these
systems are critically involved in behaviors linked to the control
of movement, these receptors may represent ideal therapeutic
targets against nigrostriatal damage and for the treatment of PD
(Quik and Wonnacott, 2011c; Quik et al., 2011b, 2012a). It is
reasonable to speculate that cotinine and/or nicotine, by target-
ing these receptors, may be beneficial against PD (Quik et al.,
2012b). In recent years, we and others have proposed that cotinine
functions as a positive allosteric modulator (PAM) of α7 nAChRs
(Echeverria and Zeitlin, 2012). Positive allosteric modulator com-
pounds enhance the response and inhibit the desensitization of
the nicotinic receptor by its agonists. Also, by using [3H] DA
release assays and ligand-binding autoradiography in monkey’s
striatum, it was discovered that cotinine functionally interacts
with both α4β2 and α3α6β2 subtypes of nicotinic receptors in the
caudate promoting DA release. This effect could prove useful for
the future development of therapies for PD (O’Leary et al., 2008).
In addition, based on previous reports showing an anti-
inflammatory effect of the nAChRs modulation (Kalra et al.,
2002, 2004), we hypothesize that cotinine may also be beneficial
reducing the neuroinflammation process observed in PD brains.
For example, an in vitro study showed an anti-inflammatory effect
of nicotine by inhibiting microglia cell activation (Guan et al.,
2014). Interestingly, cotinine suppresses the release of oxygen free
radicals from neutrophils (Srivastava et al., 1989) and augments
PI3K-dependent anti-inflammatory pathways in human mono-
cytes (Rehani et al., 2008; Figure 2).
ANABASEINE AND NICOTINE
Anabasine is a tobacco alkaloid, occuring as a mixture of
enantiomers in wild tree tobacco (Nicotinana glauca). Anaba-
sine is similar in structure to anabaseine, an alkaloid occur-
ing in certain animal venoms are toxins, but lacks the imine
double bond of anabaseine. These two compounds are mod-
ulators of the α7nAChRs. The relative agonistic potencies of
the agonists on human fetal nicotinic neuromuscular receptors
order: anabaseine >> S-anabasine > R-anabasine. Anabaseine
stimulates α7nAChRs currents at higher rates than nicotine
(65% response) and equivalent to acetylcholine in the receptor
expressed in Xenopus oocytes (Kem et al., 1997). Several nicotinic
agonists derived from anabaseine have been characterized. One
of these compounds, DMXBA [3-(2,4-dimethoxybenzylidene)-
anabaseine; code name GTS-21] is an antagonist of the α4/β2
receptors and a selective agonist of the α7 receptors. DMXBA has
shown promising characteristics in phase I studies (Kem, 2000).
One of these studies indicated that DMXBA improved cognitive
abilities and was safe when administered orally to healthy young
male subjects. DMXBA is a partial agonist of the α7 receptors, is
much less toxic than nicotine, and does not affect autonomic and
skeletal muscle systems at doses, which enhance cognitive behav-
ior. In addition, DMXBA is neuroprotective against β-amyloid
toxicity or NGF deprivation. In comparison to full agonists, par-
tial agonists only elicit a partial response still after full binding to
the α7 receptors. Because of this limited activity, partial agonists
are less toxic and addictive than full agonist (Shi et al., 2013).
A recent study investigated the effects of DMXBA, a selective
α7nAChR agonist (Briggs et al., 1997), in a rat 6-OHDA-induced
PD-like model (Suzuki et al., 2013). This model is based in the fact
that 6-OHDA when microinjected into the nigrostriatal pathway
of rats selectively induces the apoptosis of dopaminergic neu-
rons. Injection of 6-OHDA increased microgliosis and astrogliosis
markers in the SNc of rats. Dopaminergic neurodegeneration and
gliosis was markedly inhibited by co-administration of DMXBA.
This agonist prevented neuronal loss by a mechanism dependent
on the α7nAChR, since it was abolished by its selective receptor’s
antagonist methyllycaconitine since microglia in the SNc also
expresses α7nAChR in both resting and activated states (Briggs
et al., 1995). It is reasonable to propose that anabaseine by acting
on the nAChRs in neurons and glia, may prevent PD development
by reducing apoptosis and neuroinflammation (Suzuki et al.,
2013).
Similar neuroprotective effects of nicotine in the model
of rotenone-induced PD-like pathology have been previously
reported in rats (Costa et al., 2001). Both rotenone and 6-OHDA
are strong inhibitors of the mitochondrial complex I, a pro-
tein complex located at the mitochondrial inner membrane and
protruding into the matrix (Meredith et al., 2008; Kawamata
and Shimohama, 2011). This neuroprotective effect was inhib-
ited by mecamylamine, a general nAChR antagonist; the α7
specific competitive antagonist, α-bungarotoxin, and dihydro-
β-erythroidine dehydropyridine (DHPE) a potent antagonist
of the α4β2 neuronal nAChRs (Luetje et al., 1990). These
findings suggest that nicotine-induced neuroprotective effects
are mediated via nAChRs, especially through α7 and α4β2
receptors. They also showed that nicotine prevented rotenone-
induced dopaminergic neuronal death via the PI3K. Despite
these encouraging effects, nicotine is not an optimal therapeu-
tic drug because it represents a health risk for its toxicity and
addictive effects. Moreover, evidence that long-term nicotine
exposure both depressed DA release in the nucleus accumbens
of non-human primates and decreased the expression of α6β2
nAChRs in the same brain region of rats, further weakens the
enthusiasm of using nicotine as a therapy against PD (Perez
et al., 2012, 2013). About the relationship between PD and
nAChRs, a recent report investigating 596 patients suffering from
PD and 369 control subjects showed that lower expression of
the β3 nAChR subunit was associated with nicotine depen-
dance in PD. They found a significant increase of the c.-57G
allele of the CHRNB3 gene codifying for β3 nAChR among
PD patients when compared to controls. The authors suggest
that the CHRNB3c.-57 A > G change affects CHRNB3 gene
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promoter activity and that this allele is associated with PD and
smoking. They also concluded that nicotine may be especially
beneficial in PD patients with specific genotypes (Bar-Shira et al.,
2014).
SAFETY OF NICOTINE USE
Several forms of administration of nicotine has been tested in
humans including transdermal patches, gums, lozenges, tablets,
inhalers, electronic cigarettes, and nasal sprays. Nicotine replace-
ment therapies are considered safer than tobacco use, having
much less harmful effects than cigarette smoke (Schneider et al.,
2001; Caldwell et al., 2012; Gupta and Babu, 2013; Palazzolo,
2013; Sanford and Goebel, 2014). The results of several pilot
clinical studies investigating the effect of nicotine on PD’s symp-
toms suggest that nicotine or drugs modulating the nAChRs
have potential for treating PD (Kelton et al., 2000; Quik et al.,
2011a). Unfortunately, due to the small size of the cohorts and
disparities of the protocols used, these studies have not given con-
clusive results of nicotine’s efficacy in decreasing motor or non-
motor symptoms, best daily dosage or method of administration
(Thiriez et al., 2011).
Despite the experimental evidence suggesting that this alka-
loid may have different effects depending on the concentra-
tion reached in the body, nicotine is still considered a toxic
and addictive compound. High doses of nicotine may hasten
tumors and atheromas growth by promoting angiogenesis, and
neovascularization (Dasgupta and Chellappan, 2006; Pillai and
Chellappan, 2012). Additionally, the activation of nAChR by nico-
tine may increase the occurrence of choroidal neovascularization
as observed in aged smokers with macular degeneration (Davis
et al., 2012). However, low doses of nicotine seem to have different
effects. For example, nicotine used in the form of nasal spray
did not affect blood pressure and hematologic parameters in
smokers (Benowitz et al., 2002). Similarly, transdermal nicotine
did not increase the incidence of myocardial ischemia (Benowitz
and Gourlay, 1997). Neither, nicotine induced exacerbation of
arrhythmia and/or myocardial ischemia in those with preexist-
ing coronary artery disease (Benowitz and Gourlay, 1997). Sub-
stantial evidence supports the view that at low concentrations
(1–30 nM), nicotine enhances the release of vasodilators and
increases the survival of endothelial cells. Conversely, at higher
concentrations nicotine is toxic and has deleterious effects on the
vasculature (Yu et al., 2009).
As an alternative option, the reduction of the dose of nico-
tine needed for therapeutic use is currently being investigated.
For example, a recent study assessed the effect of nicotine-
encapsulated poly (lactic-co-glycolic) acid (PLGA) nanoparticles
on MPTP-induced neurotoxicity and neuroinflammation in a
mouse model of PD (Tiwari et al., 2013). As previously shown,
MPTP reduced tyrosine hydroxylase immunoreactivity and DA
levels, and increased several markers of neuroinflammation such
as microglial activation, and the expression of the inducible nitric
oxide synthase, metallothionein-III, heme oxygenase 1. 1-Methyl-
4-phenyl-1,2,3,6- tetrahydropyridine also increased the levels of
protein markers of apoptosis, such as p53 and caspase-3, as well
as markers of oxidative stress including nitrite and lipid hydroper-
oxidase in the brain. However, nicotine was neuroprotective and
improved the survival of tyrosin hydroxylase immunoreactive
neurons in the brain of mice. Both nicotine and nicotine-PLGA
nanoparticles normalized the levels of these biomarkers, but
nanotization of nicotine improved its bioavailability and effi-
cacy in reducing the indicators of oxidative stress and apoptosis
(Tiwari et al., 2013). This evidence suggests that this new delivery
approach may facilitate the use of nicotine or its metabolites
against PD.
The negative effects of nicotine can be counteracted and sev-
eral pharmacological agents have shown promises to prevent the
deleterious effects of nicotine such as the cardiovascular abnor-
malities associated with the chronic nicotine exposure. Some
evidence obtained in rodent models suggests that agents or nat-
ural extracts with antioxidant properties, such as melatonin and
oil onion may prevent the nicotine-induced myocardial injury
by activating antioxidant defense and reducing oxidative stress
(Helen et al., 1999; Baykan et al., 2008; Rodella et al., 2012).
Likewise, the administration of vitamin E reduces both oxidative
stress and endothelial dysfunction induced by cigarette smoking
(Heitzer et al., 1999).
In addition to these natural compounds, other drugs have
been tested to counteract the potential oxidative stress induced
by nicotine. For example, angiotensin, by activating type 1 recep-
tors, is a major activator of the nicotinamide adenine dinu-
cleotide phosphate-oxidase (NADPH-oxidase) complex, involved
in oxidative stress and inflammatory processes. Several studies
have demonstrated that hyperactivation of the renin-angiotensin
system in the SN and striatum may exacerbate oxidative stress
by stimulating the NADPH-oxidase activity, and the microglial
inflammatory response (Garrido-Gil et al., 2013; Labandeira-
García et al., 2014). These effects may certainly contribute to the
degeneration of dopaminergic neurons in those regions. Thus,
angiotensin receptor blockers and angiotensin converting enzyme
(ACE) inhibitors have been proposed as protective drugs against
oxidative stress and inflammation derived from smoking and also
in PD pathology (Wright and Harding, 2012).
Although a comprehensive understanding of the mechanisms
of neuroprotection by nicotine-like compounds is still in progress
(see Table 1), it is generally accepted that the activation of nAChRs
is a required step. Future clinical studies directed towards estab-
lishing the potential for nicotine metabolites to treat neurological
and psychiatric disorders for which the positive modulation of
the nAChRs have shown beneficial effects such as AD, depression,
post-traumatic stress disorder, schizophrenia and Tourette’s syn-
drome.
CONCLUDING REMARKS
Preclinical studies showed that nicotine’s metabolites that
are positive cholinergic modulators show pro-cognitive, anti-
inflammatory and neuroprotective properties associated with the
positive modulation of the cholinergic and dopaminergic systems.
Derivatives of nicotine such as cotinine have great potential to
become effective agents to prevent and alleviate neurological
symptoms developed in subjects with Parkinsonism. It is surpris-
ing the absence of funding for the clinical development of these
compounds, as they could be therapeutic solutions which have
been lying in front of our eyes for hundreds of years, waiting for
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Table 1 | Effect of Nicotine and some nicotine derivatives on Parkinson disease pathology.
Drug Dopamine Striatum Cognitive Motor References
levels Integrity/ abilities/ functions
neuroprotection Synaptic
plasticity
Nicotine (Long-term) + Costa et al. (2001)
+ Guan et al. (2014)
+ Maggio et al. (1997)
+ Parain et al. (2003)
− Perez et al. (2012)
+ + + Quik et al. (2006a,b)
+ + Tiwari et al. (2013)
+ + Yanagida et al. (2008)
Cotinine + + Buccafusco and Terry (2003)
+ Buccafusco and Terry (2009)
+ Burgess et al. (2012)
+ Dwoskin et al. (1999)
+ Echeverria et al. (2011)
+ Grizzell et al. (2014)
+ Parain et al. (2003)
+ Terry et al. (2012)
ABT-107 + + Bordia et al. (2014)
ABT-089/ + + Zhang et al. (2014)
ABT-894
DMXBA + Kem (2000)
+ + Suzuki et al. (2013)
development. The savings in public health costs will definitely
overcome the costs of the clinical testing of these compounds
and will positively affect the society as a whole by increasing the
quality of life of millions of our elder citizens.
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